What Is 7-Hydroxymitragynine? Potency and Risks

7-Hydroxymitragynine, often abbreviated as 7-OH, is a naturally occurring alkaloid found in small amounts in kratom leaves and, more importantly, an active metabolite that your body produces when it processes kratom’s main alkaloid, mitragynine. It binds to the same brain receptors as classical opioids and does so with roughly nine times the affinity of mitragynine itself, which makes it a major driver of kratom’s painkilling effects and a significant source of its risks.¹ Understanding what 7-OH actually does in the body, why it keeps showing up in regulatory debates, and how it ends up in commercial products at unnaturally high levels is more involved than the typical kratom discussion lets on.

How 7-OH Forms in the Body

When you consume kratom in any form, the dominant alkaloid entering your bloodstream is mitragynine. Your liver then converts a portion of that mitragynine into 7-hydroxymitragynine through a family of enzymes called CYP3A, with CYP3A4 being the primary human enzyme responsible.² This means that even if a kratom product contains very little 7-OH on its own, your body will manufacture it internally after you take it. The conversion is a central part of how kratom produces its opioid-like effects.

This metabolic pathway matters for a practical reason that rarely comes up in consumer discussions. CYP3A4 is one of the most heavily involved liver enzymes in drug metabolism. Dozens of common medications and even foods like grapefruit juice either inhibit or speed up CYP3A4 activity. If something slows the enzyme down, less mitragynine gets converted to 7-OH and the opioid effects shift. If something speeds it up, more 7-OH is produced from the same dose. This creates a layer of unpredictability for anyone taking kratom alongside other substances, even seemingly harmless ones, because the amount of 7-OH your body generates is not fixed. It depends heavily on what else your liver is processing at the time.

Research has also identified 7-OH as a transient precursor to yet another compound called mitragynine pseudoindoxyl, which shows even stronger opioid receptor selectivity.³ So 7-OH is not the final stop in the metabolic chain. It sits in the middle, acting as both an active compound in its own right and a stepping stone to further metabolites. This complexity is part of why pinning down kratom’s full pharmacological profile has been so difficult for researchers.

How Potent Is 7-OH Compared to Mitragynine

The potency gap between 7-OH and its parent compound mitragynine is substantial. In receptor binding studies, 7-hydroxymitragynine showed about 9.1 times higher affinity for the mu-opioid receptor than mitragynine, roughly 7.7 times higher affinity at kappa-opioid receptors, and about 28 times higher affinity at delta-opioid receptors.¹ The mu-opioid receptor is the one most associated with pain relief, euphoria, and the risk of dependence, so that roughly ninefold increase is the number that gets the most attention.

To put this in context, though, 7-OH is still far weaker than traditional opioid drugs at the same receptor. Its binding affinity at the mu-opioid receptor was at least 7.1 times lower than reference opioid ligands tested in the same study.¹ So 7-OH occupies a middle ground: much more potent than mitragynine, but less potent than morphine or fentanyl at gripping those same receptors. This middle-ground status is sometimes used to argue that kratom is inherently safer than classical opioids, and while there may be some truth to that comparison in terms of raw receptor affinity, it does not mean 7-OH is without serious risk, as the respiratory and dependence data show.

One thing that complicates potency comparisons is the concept of biased agonism. Not all compounds that activate opioid receptors trigger the same downstream effects equally. Some activate the pathways that produce pain relief more strongly than the pathways that suppress breathing. There has been interest in whether kratom alkaloids, including 7-OH, might lean toward the pain-relief side without as much respiratory risk. The evidence on this is still being worked out, and as described below, the respiratory picture is not as reassuring as some have hoped.

Respiratory Depression and the Safety Question

One of the most dangerous effects of traditional opioids is respiratory depression, where breathing slows to the point of becoming life-threatening. This is the primary mechanism behind opioid overdose deaths. Whether kratom alkaloids carry the same risk has been a major question in the research community, and the answer for 7-OH specifically is concerning. In rat studies, administration of 7-hydroxymitragynine produced robust, dose-dependent respiratory depression, meaning that as the dose went up, breathing slowed progressively and predictably.⁴

What confirmed that this breathing suppression was truly an opioid-type effect, and not some unrelated mechanism, was the response to naloxone. Naloxone is the emergency reversal drug used to treat opioid overdoses, and it successfully reversed the respiratory depression caused by 7-OH.⁴ That naloxone reversal is strong pharmacological evidence that 7-OH is acting through opioid receptors in the brainstem to suppress breathing, just like morphine or heroin would. For anyone who has been told that kratom “isn’t really an opioid” or “can’t cause an overdose,” this finding is worth sitting with.

The dose-dependent nature of the effect is also important for understanding real-world risk. At lower exposures, 7-OH may not push breathing into dangerous territory. But as the dose climbs, so does the hazard. And because 7-OH concentrations in commercial products vary wildly (more on this below), users have limited ability to control their actual exposure to this specific alkaloid, even if they think they are being careful with their kratom dose.

Abuse Potential and Dependence

Animal studies designed to evaluate whether a substance has abuse potential look at whether animals will voluntarily and repeatedly seek it out when given the chance. In self-administration studies, 7-hydroxymitragynine was self-administered by animals at high doses, and pretreatment with it increased subsequent morphine self-administration.⁵ That second finding, the cross-sensitization with morphine, is particularly worrying. It suggests that exposure to 7-OH may prime the brain’s reward circuits in ways that make other opioids more appealing afterward.

This has direct implications for people who use kratom to manage opioid withdrawal or cravings. The rationale is understandable: kratom provides some opioid-like effects that ease withdrawal symptoms, and many people have found it genuinely helpful for that purpose. But if the 7-OH produced during kratom metabolism is reinforcing the same reward pathways and potentially increasing sensitivity to stronger opioids, the long-term picture becomes more complicated than a simple “safer substitute” framing allows. It does not mean kratom cannot play a role in harm reduction for some people, but it does mean the compound driving much of that opioid-like effect carries its own dependence risk.

Reports from long-term kratom users consistently describe withdrawal symptoms when they stop: irritability, muscle aches, insomnia, and cravings that follow a recognizable opioid withdrawal pattern. While it is difficult to attribute those symptoms to 7-OH specifically versus other kratom alkaloids, the receptor binding and behavioral data make it a strong candidate as a primary contributor.

Why Commercial Products Are a Wild Card

In raw kratom leaves, 7-hydroxymitragynine is present in only trace amounts. Most of what reaches your opioid receptors as 7-OH is generated internally by your liver after you consume mitragynine. But the commercial kratom market has introduced a complication: multiple products have been found to contain 7-OH concentrations far higher than anything you would see in the unprocessed plant.⁶

These elevated levels suggest deliberate adulteration, meaning someone is either adding synthetic or extracted 7-OH to the product to boost its effects. From a marketing perspective, a more potent product builds repeat customers. From a safety perspective, it removes the natural ceiling that the liver’s conversion rate would otherwise impose. When you consume plain kratom leaf, your CYP3A4 enzymes can only convert so much mitragynine into 7-OH at a given time, which acts as a kind of built-in speed limit on how much opioid receptor activation you experience. A product spiked with extra 7-OH bypasses that limit entirely.

The practical problem for consumers is that kratom products in most markets are not subject to pharmaceutical-grade testing or labeling requirements. You have no reliable way to know how much 7-OH is in a given capsule, extract, or powder without independent lab results, and even then, batch-to-batch consistency is not guaranteed. This is especially true for concentrated extracts marketed as “enhanced” or “gold” products, which are designed to be more potent than plain leaf. Some of these products are straightforwardly stronger versions of kratom. Others contain 7-OH at levels that do not occur in nature and behave more like a semi-synthetic opioid product being sold under a botanical label.

This adulteration issue is a major driver behind regulatory efforts targeting kratom. Health agencies point to products with artificially elevated 7-OH as evidence that the unregulated market creates genuine public health hazards. Kratom advocates, meanwhile, argue that the problem is adulteration specifically, not the plant itself, and that proper regulation and testing standards would solve it without banning kratom outright. Both sides have reasonable points, but the reality on the shelf right now is that consumers face real uncertainty about what they are actually ingesting.

How CYP3A4 Variability Creates Uneven Risk

Because 7-OH formation depends on CYP3A4 enzyme activity, individual differences in that enzyme create wide variation in how much 7-OH any given person produces from the same kratom dose. Genetic polymorphisms in CYP3A4 are well documented across populations. Some people are rapid metabolizers who convert mitragynine to 7-OH efficiently, while others are slow metabolizers who produce less. This means two people taking the same kratom product can have meaningfully different 7-OH exposures, and therefore different levels of opioid receptor activation, respiratory risk, and reinforcement.

Age, liver health, and body composition also affect CYP3A4 activity. Older adults and people with liver damage tend to have reduced enzyme function, which could shift the metabolic balance in either direction depending on other factors. And as mentioned earlier, co-ingested substances are a major variable. Common CYP3A4 inhibitors include certain antifungal medications, some antibiotics, HIV protease inhibitors, and grapefruit juice. Common inducers include the herbal supplement St. John’s wort and certain anti-seizure medications. Anyone taking kratom alongside any of these is altering the rate at which their body generates 7-OH, often without knowing it.

This variability is an underappreciated part of the kratom safety discussion. Much of the debate frames kratom as uniformly mild or uniformly dangerous, but the CYP3A4 dependence means that the effective dose of 7-OH your body sees is not just a function of how much kratom you swallow. It is shaped by your genetics, your other medications, your liver health, and even your diet. Two people with very different risk profiles can be taking the exact same product and experiencing very different pharmacological realities.

The Emerging Market for Isolated 7-OH Products

A development that has accelerated regulatory concern is the appearance of products that contain isolated or concentrated 7-hydroxymitragynine as their primary active ingredient, marketed as dietary supplements or sold in convenience stores and smoke shops. These are not traditional kratom products in any meaningful sense. They are concentrated opioid receptor agonists sold in consumer packaging, often as tablets, gummies, or liquid shots with brand names that give no indication of what is actually inside.

Several states in the U.S. have responded by passing or proposing legislation that specifically targets 7-OH rather than kratom broadly. The Kratom Consumer Protection Act, adopted in various forms by multiple states, generally sets limits on the allowable concentration of 7-hydroxymitragynine in kratom products and bans synthetic versions. This approach attempts to preserve access to traditional kratom leaf while removing the most pharmacologically aggressive products from the market. Whether these laws are effectively enforced is another question, given the fragmented nature of the supplement and herbal product supply chain.

For consumers trying to navigate this landscape, the distinction between whole-leaf kratom and 7-OH-concentrated products is the single most important practical consideration. Whole-leaf kratom, while not without risk, delivers 7-OH primarily through the bottleneck of your liver’s metabolic capacity. Products containing pre-formed 7-OH in concentrated amounts bypass that bottleneck and deliver a more directly opioid-like experience with correspondingly higher risk of respiratory depression, dependence, and unpredictable dosing. Recognizing that difference does not require taking a position on whether kratom should be legal or illegal. It just requires understanding that the alkaloid profile of what you are consuming determines the risk profile, and products vary enormously in that regard.